CompletedPhase 1NCT02750345
Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)
Studying Tyrosinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cycle Pharmaceuticals Ltd.
- Principal Investigator
- André Nell+27 51 410 3046
- Intervention
- Nitisinone(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2016 – 2016
Study locations (1)
- Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa
Collaborators
Parexel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02750345 on ClinicalTrials.gov